Parabilis Medicines is a preclinical stage biopharmaceutical company dedicated to the discovery and development of innovative protein-replacement therapies. Their primary focus is on addressing rare genetic diseases that currently have significant unmet medical needs, aiming to provide transformative treatments for patients. The company leverages scientific expertise to advance its pipeline of potential therapeutics through rigorous preclinical research.
Serves as the central hub for research and development operations, strategic planning, and corporate administration.
Located in a prominent San Diego biotech corridor, likely providing access to modern laboratory facilities and collaborative office spaces designed for scientific innovation.
Characterized by a science-driven, innovative, and collaborative environment typical of early-stage biotechnology firms. Emphasis is placed on research excellence, agility, and a patient-focused mission.
Strategic positioning within the San Diego life sciences cluster offers access to a rich talent pool, leading research institutions, and a supportive ecosystem for biotech advancement.
Currently, Parabilis Medicines is primarily focused on its preclinical research and development activities based in the United States. As the company's therapeutic candidates advance, its global functions and presence may expand to support clinical trials, regulatory affairs, and potential commercialization in key international markets.
9920 Pacific Heights Blvd., Suite 150
San Diego
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Parabilis Medicines' leadership includes:
Parabilis Medicines has been backed by several prominent investors over the years, including:
No significant executive hires or departures have been publicly announced for Parabilis Medicines in the last 12 months. The company maintains a stable core leadership team focused on advancing its preclinical programs.
Discover the tools Parabilis Medicines uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for companies like Parabilis Medicines often utilize a combination of the employee's first initial and last name, or first name and last name, followed by the company domain. For example, an employee named Jane Doe might have an email address like jdoe@parabilismedicines.com.
[first_initial][last]@parabilismedicines.com
Format
hboudreau@parabilismedicines.com
Example
75%
Success rate
Company Website & Industry Observation • March 15, 2024
Parabilis Medicines continues its dedicated work in the preclinical phase, focusing on the development of its innovative protein-replacement therapies. The company's efforts are concentrated on validating its therapeutic candidates for rare genetic diseases with high unmet medical needs, with ongoing research to support future clinical development....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Parabilis Medicines, are just a search away.